

Biologistex LLC and MNX Global Logistics Partner to Offer Enhanced Cold Chain Logistics Services for Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies

MNX Same Day/Next Flight Out Door to Door Logistics Services to be Available in biologistex™ Cloud-Based Cold Chain App

BOTHELL, Wash. and IRVINE, Calif., April 26, 2016 [/PRNewswire/](#) -- Biologistex CCM, LLC, a joint venture of [BioLife Solutions, Inc.](#) (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue [hypothermic storage](#) and [cryopreservation freeze](#) media and a related [cloud hosted biologistics cold chain management app for smart shippers](#), and [SAVSU Technologies, LLC](#), a leading designer and manufacturer of innovative high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, today announced a partnership with [MNX Global Logistics](#), a premier global provider of specialized, expedited transportation and logistics services, to offer enhanced cold chain logistics services to the biopharma, biobanking, and regenerative medicine markets via the biologistex SaaS app.

MNX serves hundreds of customers that ship life saving, time and temperature sensitive biologic materials around the world every day. MNX offers specialized, expedited transportation and logistics services to ensure mission critical APIs, cord blood, manufactured cell products, and other biologics are securely transported and delivered on time to the intended destination.

BioLife Solutions has built a franchise in the regenerative medicine market by gaining a critical mass of cell therapy customers including most of the private and public immuno-oncology companies developing various T cell immunotherapies to treat blood cancers and solid tumors. To date, BioLife's [CryoStor®](#) and [HypoThermosol®](#) biopreservation media products have been embedded into more than 200 pre-clinical validations and clinical trials of novel cell based products and therapies targeting the leading causes of death and disability.

SAVSU Technologies is the designer and supplier of the award winning evo™ Smart Shipper to the biologistex joint venture.

MNX and biologistex have agreed to integrate their respective IT systems to enable users of the biologistex cloud based cold chain logistics app to directly order and purchase MNX support and logistic services, including next flight out, same day delivery and door to door professional courier pickup and delivery of time and temperature sensitive biologic shipments.

"We continually add products and services to our offering that enhance the value that we bring to our customers," said Paul J. Martins, Chief Executive Officer at MNX. "The evo Smart Shipper and biologistex cloud SaaS complement our drive to leverage cutting-edge technologies that help simplify cold-chain shipments for customers in the cell therapy and regenerative medicine markets."

Mike Rice, BioLife's President & CEO, remarked, "We are very pleased about our partnership with MNX, a global, best in class cold chain support services provider, and are excited to promote their logistics and support services to our customers via the biologistex app. A key goal of our biologistex joint venture with SAVSU Technologies is to provide organic and partner solutions to help our life sciences customers optimize cold chain logistics for scalable, secure distribution of time and temperature sensitive source material and manufactured biologic products including CAR T-cell therapies. MNX logistics services, specifically door to door same day delivery, offer our customers the peace of mind of secure delivery of life saving cell-based therapies, with enhanced shipment monitoring and alerts at a fraction of the cost of traditional specialty couriers, while eliminating the risk of delayed shipment delivery from multi-leg air cargo flights and the potential for packages to get stuck in a connecting hub."

About MNX Global Logistics

MNX is a premier global provider of specialized, expedited transportation and logistics services. Clients include multinational leaders in the aviation, life science, medical device, secure custody and control and entertainment industries. These organizations rely on MNX's exceptional record of transporting time-critical items around the world.

Headquartered in Irvine, CA, MNX maintains regional headquarters in Singapore, Amsterdam and Miami. MNX serves over 190 countries, including key Asia Pacific, South American and EMEA markets. www.mnx.com

About biologistex Cold Chain SaaS App:

The [biologistex](#) cloud based cold chain management service is a new integrated logistics and track and trace web app used by shippers of time and temperature sensitive biologic materials. The [evo Smart Shipper](#) is a state of the art precision thermal

shipping container with embedded payload monitoring, GPS location tracking, and cellular communication electronics that transmit critical shipment information to the cloud. This SaaS app enables users to monitor high value shipments during transit and configure actionable alerts for downstream recipients for location, approaching destination, delivery, package open, and remaining shelf life or stability via the patent pending StableAlert® countdown timer.

Addressable Markets

- In July 2015, Frost & Sullivan forecasted that the stem cell therapy market is expected to be worth \$40 billion by 2020 and \$180 billion by 2030.
- Pharmaceutical Commerce estimates that in 2015, \$10 billion was spent on cold chain logistics of pharmaceuticals, with \$7 billion for transportation and \$3 billion for specialized packaging and instrumentation. BioLife's addressable market is comprised of the demand for small payload shipping containers and related temperature monitoring and location tracking devices.

About BioLife Solutions:

The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. For more information please visit www.biolifesolutions.com, and follow BioLife on [Twitter](#).

About SAVSU Technologies:

SAVSU is a leading designer and manufacturer of innovative high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU® has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit www.savsu.com.

This press release contains forward-looking statements, including, but not limited to, statements concerning new products, the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, and, projected financial results and liquidity. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations

BioLife Solutions, Inc.
Roderick de Greef
Interim Chief Financial Officer
(425) 402-1400
rdegreef@biolifesolutions.com

Media & Investor

Relations

MNX Global Logistics
Ken Ying
Global Director of Marketing
(310) 981-0919
kenneth.ying@mnx.com

SOURCE BioLife Solutions, Inc.

<https://investors.biolifesolutions.com/2016-04-26-Biologistex-LLC-and-MNX-Global-Logistics-Partner-to-Offer-Enhanced-Cold-Chain-Logistics-Services-for-Time-and-Temperature-Sensitive-Biologics-Vaccines-Cell-Therapies>